Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Dec 8;19(12):3946.
doi: 10.3390/ijms19123946.

Sulfonamide Inhibition Studies of a New β-Carbonic Anhydrase from the Pathogenic Protozoan Entamoeba histolytica

Affiliations

Sulfonamide Inhibition Studies of a New β-Carbonic Anhydrase from the Pathogenic Protozoan Entamoeba histolytica

Silvia Bua et al. Int J Mol Sci. .

Abstract

A newly described β-carbonic anhydrase (CA, EC 4.2.1.1) from the pathogenic protozoan Entamoeba histolytica, EhiCA, was recently shown to possess a significant catalytic activity for the physiologic CO₂ hydration reaction (kcat of 6.7 × 10⁵ s-1 and a kcat/Km of 8.9 × 10⁷ M-1 s-1). A panel of sulphonamides and one sulfamate, some of which are clinically used drugs, were investigated for their inhibitory properties against EhiCA. The best inhibitors detected in the study were 4-hydroxymethyl/ethyl-benzenesulfonamide (KIs of 36⁻89 nM), whereas some sulfanilyl-sulfonamides showed activities in the range of 285⁻331 nM. Acetazolamide, methazolamide, ethoxzolamide, and dichlorophenamide were less effective inhibitors (KIs of 509⁻845 nM) compared to other sulfonamides investigated here. As β-CAs are not present in vertebrates, the present study may be useful for detecting lead compounds for the design of more effective inhibitors with potential to develop anti-infectives with alternative mechanisms of action.

Keywords: Entamoeba histolytica; carbonic anhydrase; inhibitor; metalloenzymes; protozoan; sulfamates; sulfonamides.

PubMed Disclaimer

Conflict of interest statement

The authors do not declare conflict of interest.

Figures

Figure 1
Figure 1
Multi-alignment of the amino acid sequences of the β-CAs from M. tuberculosis (isoform MTCA1_MYCTU), Synechocystis sp. (SYNY3), V. cholerae (VIBCL), H. influenzae (HAEIN), E. coli (ECOLI), S. typhimurium (SALTY), E. histolytica (ENTHI), and M. tuberculosis (isoform MTCA2_MYCTO) [21,30,31,32,33,34,35,36]. Conserved amino acids depicted by an asterisk (*), semiconserved ones by (.) or (:).
Figure 2
Figure 2
Sulfonamide (1–24) and sulfonamide/sulfamate derivatives (AAZ–HCT) investigated as Entamoeba histolytica (EhiCA) inhibitors in the present study.
Figure 2
Figure 2
Sulfonamide (1–24) and sulfonamide/sulfamate derivatives (AAZ–HCT) investigated as Entamoeba histolytica (EhiCA) inhibitors in the present study.

Similar articles

Cited by

References

    1. Sánchez C., López M.C., Galeano L.A., Qvarnstrom Y., Houghton K., Ramírez J.D. Molecular detection and genotyping of pathogenic protozoan parasites in raw and treated water samples from southwest Colombia. Parasit. Vectors. 2018;11:563. doi: 10.1186/s13071-018-3147-3. - DOI - PMC - PubMed
    1. Domazetovska A., Lee R., Adhikari C., Watts M., Gilroy N., Stark D., Sivagnanam S. A 12-Year Retrospective Study of Invasive Amoebiasis in Western Sydney: Evidence of Local Acquisition. Trop. Med. Infect. Dis. 2018;3:73. doi: 10.3390/tropicalmed3030073. - DOI - PMC - PubMed
    1. Costa J.O., Resende J.A., Gil F.F., Santos J.F.G., Gomes M.A. Prevalence of Entamoeba histolytica and other enteral parasitic diseases in the metropolitan region of Belo Horizonte, Brazil. A cross-sectional study. Sao Paulo Med. J. 2018;136:319–323. doi: 10.1590/1516-3180.2018.0036170418. - DOI - PMC - PubMed
    1. Shirley D.T., Farr L., Watanabe K., Moonah S. A Review of the Global Burden, New Diagnostics, and Current Therapeutics for Amebiasis. Open Forum Infect. Dis. 2018;5:ofy161. doi: 10.1093/ofid/ofy161. - DOI - PMC - PubMed
    1. Hashmey N., Genta N., White N., Jr. Parasites and Diarrhea. I: Protozoans and Diarrhea. J. Travel. Med. 1997;4:17–31. doi: 10.1111/j.1708-8305.1997.tb00769.x. - DOI - PubMed

MeSH terms